ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of nemolizumab ...
Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the ...
Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by firm, itchy, and often painful bumps (nodules) on the skin. It typically begins with intense itchiness, which can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results